News

– $76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited – sNDA for LIVMARLI in PFIC submission planned for first quarter 2023 – Multiple data analyses planned in 2023 advancing late-stage cholestasis programs FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided a preview…

FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023. Presentation and Q&A Session Visit the Investors and Media section of…